Clinical trial
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML…
NCT00303667 · Masonic Cancer Center, University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00303667 |
|---|---|
| Title | Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant |
| Official title | Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsuitable for Fully Myeloablative Transplantation |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | aldesleukin, natural killer cells, cyclophosphamide, fludarabine phosphate, allogeneic hematopoietic stem cell transplantation, total body irradiation, Thymoglobulin, Cyclosporin A |
| Enrollment | 50 |
| Start date | Jan 1, 2005 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Mar 17, 2006 |
| Last update posted | Dec 28, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: